Manteinance interferon (IFN) does not increase progression free survival (PFS) in patients with indolent non Hodgkin's lymphoma (NHL) who received IFN in the induction treatment. Results from a randomized trial on 165 patients
ANNALS OF ONCOLOGY（2005）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要